MARCHESELLI, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.278
AS - Asia 9.172
EU - Europa 8.786
SA - Sud America 1.171
OC - Oceania 549
Continente sconosciuto - Info sul continente non disponibili 426
AF - Africa 415
Totale 41.797
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.463
GB - Regno Unito 2.989
SG - Singapore 1.991
CN - Cina 1.726
IT - Italia 1.471
HK - Hong Kong 917
VN - Vietnam 869
DE - Germania 851
BR - Brasile 830
SE - Svezia 632
PH - Filippine 567
CA - Canada 542
AU - Australia 502
TR - Turchia 476
FI - Finlandia 446
FR - Francia 443
BD - Bangladesh 369
RU - Federazione Russa 345
IN - India 298
UA - Ucraina 289
IR - Iran 288
KR - Corea 209
PK - Pakistan 193
ID - Indonesia 165
JP - Giappone 159
NL - Olanda 146
IE - Irlanda 140
MY - Malesia 125
ES - Italia 122
BG - Bulgaria 119
PL - Polonia 118
ZA - Sudafrica 113
AR - Argentina 110
MX - Messico 106
GR - Grecia 100
SA - Arabia Saudita 95
IL - Israele 87
IQ - Iraq 87
TW - Taiwan 86
MA - Marocco 77
BE - Belgio 71
AT - Austria 66
NP - Nepal 61
TH - Thailandia 61
AE - Emirati Arabi Uniti 57
EC - Ecuador 52
RO - Romania 49
CO - Colombia 47
LK - Sri Lanka 47
NZ - Nuova Zelanda 46
JO - Giordania 44
KE - Kenya 44
NO - Norvegia 44
GE - Georgia 39
EG - Egitto 38
LT - Lituania 37
CH - Svizzera 35
CL - Cile 35
LV - Lettonia 34
PT - Portogallo 31
CZ - Repubblica Ceca 30
EE - Estonia 30
HR - Croazia 25
VE - Venezuela 24
NG - Nigeria 23
HU - Ungheria 22
TN - Tunisia 22
BA - Bosnia-Erzegovina 21
CR - Costa Rica 21
PE - Perù 21
UZ - Uzbekistan 21
JM - Giamaica 20
SI - Slovenia 18
SK - Slovacchia (Repubblica Slovacca) 18
DZ - Algeria 17
OM - Oman 17
PY - Paraguay 17
TT - Trinidad e Tobago 16
BZ - Belize 15
BH - Bahrain 14
BO - Bolivia 14
PR - Porto Rico 14
UG - Uganda 14
UY - Uruguay 13
LB - Libano 12
AZ - Azerbaigian 11
DK - Danimarca 11
DO - Repubblica Dominicana 11
NI - Nicaragua 11
CY - Cipro 10
ET - Etiopia 10
SV - El Salvador 10
HN - Honduras 9
MU - Mauritius 9
PA - Panama 9
PS - Palestinian Territory 9
GT - Guatemala 8
KZ - Kazakistan 8
QA - Qatar 8
LY - Libia 7
Totale 41.219
Salva come PNG Salva come JPEG
Città #
Ashburn 2.338
Fairfield 1.815
Southend 1.619
Santa Clara 1.447
Singapore 1.244
Woodbridge 1.143
Chandler 839
Houston 837
Hong Kong 818
San Jose 790
Seattle 698
Wilmington 660
Cambridge 591
Council Bluffs 529
Jacksonville 510
Dearborn 428
Ann Arbor 404
Nyköping 401
Beijing 382
Hefei 370
Los Angeles 359
London 344
Helsinki 332
New York 293
Chicago 290
Ho Chi Minh City 276
Modena 231
Hanoi 230
Frankfurt am Main 224
Milan 184
Redwood City 183
Munich 181
San Diego 180
The Dalles 170
Izmir 154
Dallas 137
Seoul 131
Shanghai 123
Princeton 116
Sofia 113
Salt Lake City 112
Buffalo 108
Melbourne 106
São Paulo 103
Columbus 97
Eugene 96
Moscow 94
Lauterbourg 88
Boardman 83
Jakarta 81
Tokyo 81
Sydney 78
Manchester 77
Dublin 76
Istanbul 71
Phoenix 71
Toronto 67
Ottawa 62
Brisbane 61
Bremen 59
Bologna 58
Rome 55
Elk Grove Village 53
Warsaw 53
Montreal 51
Tampa 50
Atlanta 49
Paris 48
Falls Church 47
Taipei 46
Boston 44
Athens 43
Denver 43
Liverpool 43
North Bergen 43
Quezon City 43
Johannesburg 42
Da Nang 41
Des Moines 41
Miami 41
Brussels 40
Philadelphia 39
Casablanca 38
Orem 38
Tehran 38
Brooklyn 37
Colombo 37
Fremont 37
Kuala Lumpur 37
Karachi 36
Islamabad 35
Lahore 35
Riyadh 35
Dong Ket 34
Stockholm 34
Amsterdam 33
Birmingham 32
Cebu City 32
Manila 32
Perth 32
Totale 25.430
Salva come PNG Salva come JPEG
Nome #
Empathy and burnout: an analytic cross-sectional study among nurses and nursing students 7.105
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 728
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 648
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 638
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 569
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 564
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 549
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 515
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 501
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 486
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 476
Empathic attitudes among nursing students: a preliminary study 438
The impact of shift work on the psychological and physical health of nurses in a general hospital: a comparison between rotating night shifts and day shifts 435
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 422
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 406
Identification of protein clusters predictive of response to chemotherapy in breast cancer patients 405
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 404
N,N-DIMETHYLFORMAMIDE-2-METHOXYETHANOL SOLVENT SYSTEM - DENSITIES AND EXCESS MOLAR VOLUMES AT VARIOUS TEMPERATURES 401
The outcome of peripheral t-cell lymphoma patients failing first-line therapy: A report from the prospective, international t-cell project 401
Incidence, clinical features and possible etiology of early onset (≤40 years) colorectal neoplasms. 397
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 394
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 389
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 383
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 382
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 377
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 373
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 373
A NON-LINEAR CORRELATION MODEL FOR THE RELATIVE PERMITTIVITY OF TERNARY AMPHIPROTIC (SOLVENT) MIXTURES 367
Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi 365
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 365
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 363
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis 362
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 358
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 347
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 346
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network 344
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 341
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study 337
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 337
ANALYSIS OF HEAVY-METALS IN ACETO-BALSAMICO-TRADIZIONALE-DI-MODENA BY FLAME ATOMIC-ABSORPTION SPECTROSCOPY 336
Cancer incidence, mortality, and survival in Eastern Libya: Updated report from the Benghazi Cancer Registry 335
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 334
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 333
Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial 333
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 332
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 331
Watchful waiting in low-tumorburden follicular lymphoma in the Rituximab era. Results of a F2 observational 327
Durability and efficacy of tibial arterial stent placement for critical limb ischemia 327
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 326
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 325
2-methoxyethanol - water solvent system : static relative permittivity from -10 to 80°C 323
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 323
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas 322
Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: A population-based study 322
Prognostic relevance of microsatellite instability in pT3N0M0 colon cancer: a population-based study 321
Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi 320
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 320
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study 315
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 312
CLIPI: a new prognostic index for indolent cutaneos B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 311
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 307
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 306
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 304
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 304
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 303
Multicentre validation of an immune-inflammation-based nomogram to predict survival in western resectable gastroesophageal adenocarcinoma: The NOMOGAST 300
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi 297
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 296
Dielectric properties of ethane-1,2-diol + 2-methoxyethanol + water liquid ternary mixtures 294
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi 294
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL) 293
Estimating survival in newly diagnosed cancer patients: use of computer simulations to evaluate performances of different approaches in a wide range of scenarios. 291
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study 284
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 282
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. 281
Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. 279
The relative permittivity of the ternary 1,2-ethanediol + 2-methoxyethanol + water solvent system 275
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 270
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 270
I tumori nelle provincie di Parma, Reggio Emilia, Modena 266
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 264
Twenty-years experience with de novo metastatic breast cancer 257
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 252
Contemporary economic and clinical evaluations of endovascular repair for intact descending thoracic aortic aneurysms 252
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 250
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 249
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 248
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 243
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 241
The Relative Permittivity of N,N-Dimethylformamide/1,2-Dimethoxyethane Binary Mixtures from -10 to 40 C 240
Standard “off-the-shelf” multibranched thoracoabdominal endograft in urgent and elective patients with single and staged procedures in a multicenter experience 236
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment 235
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 233
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas 228
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) 227
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. 224
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma 224
Phase II Fludarabine and Cyclophosphamide for the treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi. 219
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study 216
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma 209
Totale 40.762
Salva come PNG Salva come JPEG
Categoria #
all - tutte 134.625
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 134.625
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.314 0 0 0 194 143 218 170 207 338 260 489 295
2022/20233.279 285 357 233 328 359 401 144 304 390 151 180 147
2023/20243.220 111 149 218 250 622 263 469 377 110 180 218 253
2024/20255.924 195 113 193 476 1.102 779 476 436 680 269 502 703
2025/202610.466 658 424 690 1.193 1.679 785 1.181 522 959 975 806 594
2026/20272.909 368 801 721 1.019 0 0 0 0 0 0 0 0
Totale 41.797